Heron Therapeutics, Inc. Closes Underwritten Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Heron Therapeutics (HRTX) Announces Initiation of HTX-011 Phase 2
June 16, 2015 8:02 AM EDTHeron Therapeutics (NASDAQ: HRTX) has initiated a Phase 2 clinical trial of HTX-011, the Companys lead product candidate for the prevention of post-operative pain, following clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for HTX-011. HTX-011, which utilizes Herons proprietary... More
